{"product_id":"coherus-swot-analysis","title":"Coherus Biosciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCoherus Biosciences leverages strong biosimilar product pipelines and strategic partnerships, but faces intense competition and regulatory hurdles. Understanding these dynamics is crucial for any investor or industry professional.\u003c\/p\u003e\n\u003cp\u003eDiscover the complete picture behind Coherus Biosciences' market position with our full SWOT analysis. This in-depth report reveals actionable insights, financial context, and strategic takeaways—ideal for entrepreneurs, analysts, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus BioSciences has strategically pivoted to become an innovative oncology company, concentrating its efforts on cancer treatment. This focused approach allows for dedicated research and development, aiming to secure a leading role in a high-value therapeutic sector.\u003c\/p\u003e\n\u003cp\u003eThis specialization is crucial given the significant market potential in oncology. For instance, the global oncology market was valued at approximately $200 billion in 2023 and is projected to grow substantially, reaching over $300 billion by 2028, according to various market analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLOQTORZI (Toripalimab) as a Key Product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLOQTORZI (toripalimab) stands out as a significant strength for Coherus Biosciences, being the first and only FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma (NPC) across all lines of therapy and patient populations. This exclusive market position in NPC, a disease with a substantial unmet need, creates a robust commercial opportunity and a strong foundation for revenue generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Immuno-Oncology Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences’ strength lies in its robust immuno-oncology pipeline, extending beyond its approved LOQTORZI. Promising candidates such as casdozokitug, an IL-27 antagonist, and CHS-114, an anti-CCR8 antibody, are in development for various solid tumors.\u003c\/p\u003e\n\u003cp\u003eThese pipeline assets are strategically designed to potentially complement LOQTORZI, offering synergistic effects that could broaden therapeutic applications and market penetration. This diversified approach positions Coherus for significant growth in the competitive oncology landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Divestiture and Improved Financial Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences significantly bolstered its financial standing through the strategic divestiture of its UDENYCA biosimilar franchise in early 2025. This transaction yielded substantial cash consideration, injecting vital capital into the company. \u003c\/p\u003e\n\u003cp\u003eThe infusion of cash has dramatically improved Coherus's capital structure and cash position. This strategic move provides the company with a cash runway extending beyond two years, critically supporting the ongoing development of its oncology pipeline. \u003c\/p\u003e\n\u003cp\u003eThis divestiture also serves to streamline Coherus's business model, enabling a sharper focus on its core oncology strategy. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Capital Structure:\u003c\/strong\u003e The UDENYCA divestiture in early 2025 provided a significant cash inflow, strengthening Coherus's balance sheet. \u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExtended Cash Runway:\u003c\/strong\u003e The company now has over two years of operating capital, crucial for advancing its oncology pipeline. \u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Focus:\u003c\/strong\u003e The divestiture allows Coherus to concentrate resources and efforts on its core oncology business. \u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Commercial Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences has a strong track record of commercial execution, especially within the competitive oncology landscape. This established expertise is vital for effectively launching and scaling new treatments, ensuring they reach the patients who need them.\u003c\/p\u003e\n\u003cp\u003eTheir proven ability to navigate complex market dynamics, including sales, marketing, and distribution, is a significant asset. This is particularly relevant as Coherus advances its pipeline, aiming to leverage these capabilities for future product successes.\u003c\/p\u003e\n\u003cp\u003eThe company’s commercial infrastructure is well-positioned to support the anticipated growth from its immuno-oncology portfolio. For instance, Coherus reported total revenue of $227.8 million for the first quarter of 2024, demonstrating ongoing commercial activity and market presence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProven Oncology Commercialization:\u003c\/strong\u003e Demonstrated success in launching and marketing oncology products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSynergistic Pipeline Integration:\u003c\/strong\u003e Capabilities are expected to bolster the commercialization of their immuno-oncology pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access Expertise:\u003c\/strong\u003e Experience in navigating payer landscapes and securing market access for therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Generation:\u003c\/strong\u003e Q1 2024 revenue of $227.8 million underscores existing commercial strength.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Dominance: Exclusive Product and Robust Pipeline Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences benefits from a strong, focused strategy centered on oncology, a rapidly expanding market. Their flagship product, LOQTORZI, is the sole FDA-approved PD-1 inhibitor for all lines of nasopharyngeal carcinoma treatment, offering a significant competitive advantage. The company's robust immuno-oncology pipeline, featuring promising candidates like casdozokitug and CHS-114, further solidifies its growth potential.\u003c\/p\u003e\n\u003cp\u003eThe divestiture of the UDENYCA biosimilar franchise in early 2025 provided Coherus with substantial capital, extending its cash runway beyond two years and enabling a dedicated focus on its oncology ambitions. This strategic financial maneuver, coupled with proven commercial execution in the oncology sector, as evidenced by $227.8 million in Q1 2024 revenue, positions the company for successful product launches and market penetration.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrength\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Fact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLOQTORZI Market Exclusivity\u003c\/td\u003e\n\u003ctd\u003eFirst and only FDA-approved PD-1 inhibitor for all lines of therapy in nasopharyngeal carcinoma.\u003c\/td\u003e\n\u003ctd\u003eSole FDA approval for NPC across all lines of therapy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobust Immuno-Oncology Pipeline\u003c\/td\u003e\n\u003ctd\u003eDevelopment of promising candidates like casdozokitug (IL-27 antagonist) and CHS-114 (anti-CCR8 antibody).\u003c\/td\u003e\n\u003ctd\u003ePipeline assets targeting various solid tumors.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhanced Financial Position\u003c\/td\u003e\n\u003ctd\u003eSignificant cash infusion from UDENYCA divestiture in early 2025.\u003c\/td\u003e\n\u003ctd\u003eCash runway extending beyond two years.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProven Commercial Execution\u003c\/td\u003e\n\u003ctd\u003eTrack record of successful commercialization in the oncology space.\u003c\/td\u003e\n\u003ctd\u003eQ1 2024 revenue of $227.8 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Coherus Biosciences’s internal and external business factors, highlighting its established biosimilar portfolio and market expansion opportunities alongside potential regulatory hurdles and competitive pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCoherus Biosciences' SWOT analysis provides a clear roadmap for navigating market complexities, offering a pain point reliever by highlighting competitive advantages and mitigating potential weaknesses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransition from Biosimilars to Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus' transition from a biosimilar focus to a pure-play oncology company presents a significant strategic shift, carrying inherent risks. This refocusing necessitates establishing a new market identity, potentially impacting brand perception and investor confidence during the adjustment period.\u003c\/p\u003e\n\u003cp\u003eThe divestiture of biosimilar assets and the reallocation of resources to oncology development and commercialization can lead to operational disruptions. For instance, Coherus announced in late 2023 its intention to divest its U.S. biosimilar business, aiming to sharpen its focus on its oncology pipeline, which includes potential blockbuster drugs like toripalimab.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on LOQTORZI for Immediate Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences' immediate revenue stream is significantly dependent on LOQTORZI following the divestiture of UDENYCA.  While LOQTORZI targets a specific niche with its unique indication for nasopharyngeal carcinoma, its early sales performance has been modest.  For instance, in the first quarter of 2024, LOQTORZI generated $10.7 million in net sales, which, while showing growth, highlights the challenge of rapidly scaling revenue to meet commercialization costs and company projections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition in the Oncology Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe oncology market is incredibly crowded, featuring many large, well-established companies alongside innovative new players.  Coherus' promising pipeline, while a strength, will undoubtedly encounter substantial competition from other firms working on comparable or even different approaches to cancer treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe success of Coherus Biosciences' pipeline, including promising candidates like casdozokitug and CHS-114, hinges critically on achieving positive outcomes in ongoing clinical trials.  The inherent unpredictability of drug development means that trial results can significantly impact future revenue projections.\u003c\/p\u003e\n\u003cp\u003eDrug development is a notoriously high-risk endeavor, characterized by substantial failure rates and extended development timelines. For instance, the pharmaceutical industry often sees failure rates exceeding 90% for drugs entering Phase 1 clinical trials. This reality poses a significant challenge for Coherus, as setbacks in trials for its key candidates could delay or even derail anticipated market entry and revenue generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Trial Dependence:\u003c\/strong\u003e Coherus' future financial performance is directly tied to the successful completion of clinical trials for its pipeline assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Failure Rates:\u003c\/strong\u003e The pharmaceutical industry's historical data indicates a challenging path through clinical development, with many drug candidates failing to reach approval.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTimeline and Cost Overruns:\u003c\/strong\u003e Lengthy trial durations and potential for unexpected results can lead to significant cost increases and delays, impacting Coherus' ability to bring products to market efficiently.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential for Supply Chain Interruptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences has faced challenges with supply chain reliability, notably experiencing temporary interruptions with products like UDENYCA in late 2024. While the UDENYCA business has since been sold, any recurrence of supply chain disruptions for their remaining oncology portfolio could significantly hinder revenue streams and damage market confidence.\u003c\/p\u003e\n\u003cp\u003eThese past issues highlight a vulnerability that could impact the company's ability to meet demand for its key products. For instance, if a critical oncology drug experiences a shortage, it could lead to lost sales and potentially allow competitors to gain market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePast Supply Disruption:\u003c\/strong\u003e Experienced temporary interruptions with UDENYCA in late 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImpact of Future Disruptions:\u003c\/strong\u003e Could negatively affect revenue and market perception for remaining oncology products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Landscape:\u003c\/strong\u003e Supply issues can create opportunities for competitors to capture market share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoherus' Oncology Bet: High Stakes, Slow Start\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus' strategic pivot to oncology, while promising, leaves it heavily reliant on the early commercial success of LOQTORZI. The nasopharyngeal carcinoma market is niche, and LOQTORZI's Q1 2024 net sales of $10.7 million indicate a slow ramp-up. This dependence creates a significant revenue gap, especially after divesting the UDENYCA biosimilar business.\u003c\/p\u003e\n\u003cp\u003eThe company faces immense pressure to navigate the competitive oncology landscape, where established players and emerging biotechs vie for market share. Success hinges on demonstrating clear clinical differentiation and effective market penetration against numerous therapeutic options.\u003c\/p\u003e\n\u003cp\u003eFurthermore, the inherent risks of drug development, with historical failure rates exceeding 90% for drugs entering Phase 1, pose a substantial threat to Coherus' pipeline. Delays or failures in clinical trials for key assets like casdozokitug and CHS-114 could severely impact future revenue projections and strategic execution.\u003c\/p\u003e\n\u003cp\u003ePast supply chain issues, such as those experienced with UDENYCA in late 2024, highlight a potential vulnerability. Any future disruptions in the supply of its oncology products could lead to lost sales and damage market confidence, especially in a sector where consistent availability is critical.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eCoherus Biosciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Coherus Biosciences SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It provides a comprehensive overview of the company's internal strengths and weaknesses, as well as external opportunities and threats.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version, offering detailed insights into Coherus Biosciences' strategic position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610686177657,"sku":"coherus-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/coherus-swot-analysis.png?v=1754743927","url":"https:\/\/growthsharematrix.com\/products\/coherus-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}